Chidozie Ugwumba sold $27k of HLSQ
other at BiomX Inc.. 74,955 shares at an average of $0.35, traded Oct 17, 2022, filed Nov 14, 2022.
Score components
- +8RoleOther
- +5Trade size$27k at market
- 0Share of holdings soldSold 2.4% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001014108-22-000163, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 17, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -8,098 | $0.34 | $2,713 | 3,063,882 | Nov 14, 2022 |
| Oct 18, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -15,300 | $0.35 | $5,294 | 3,048,582 | Nov 14, 2022 |
| Oct 19, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -4,501 | $0.37 | $1,652 | 3,044,081 | Nov 14, 2022 |
| Oct 20, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -6,636 | $0.37 | $2,482 | 3,037,445 | Nov 14, 2022 |
| Oct 21, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -5,400 | $0.37 | $1,998 | 3,032,045 | Nov 14, 2022 |
| Oct 24, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -5,900 | $0.35 | $2,059 | 3,026,145 | Nov 14, 2022 |
| Oct 25, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -3,072 | $0.37 | $1,121 | 3,023,073 | Nov 14, 2022 |
| Oct 26, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -12,500 | $0.35 | $4,325 | 3,010,573 | Nov 14, 2022 |
| Oct 27, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -1,505 | $0.36 | $548 | 3,009,068 | Nov 14, 2022 |
| Oct 28, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -1,526 | $0.36 | $543 | 3,007,542 | Nov 14, 2022 |
| Oct 31, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -3,300 | $0.37 | $1,224 | 3,004,242 | Nov 14, 2022 |
| Nov 1, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -1,300 | $0.36 | $473 | 3,002,942 | Nov 14, 2022 |
| Nov 2, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -2,416 | $0.36 | $867 | 3,000,526 | Nov 14, 2022 |
| Nov 3, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -2,000 | $0.37 | $732 | 2,998,526 | Nov 14, 2022 |
| Nov 4, 2022 | SOpen-market sale Common Stockindirect: By SymBiosis, LLC | -1,501 | $0.38 | $567 | 2,997,025 | Nov 14, 2022 |
Related signals
Other insiders at BiomX Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 60Notable | HLSQsell BiomX Inc. | Reuven Yeganeh director, owner | $4.9M 980,000 shares | -218% | |
| 60Notable | HLSQsell BiomX Inc. | Reuven Yeganeh director, owner | $3.4M 670,000 shares | -223% | |
| 12Weak | HLSQsell BiomX Inc. | OrbiMed Israel BioFund GP Limited Partnership owner | $9,280 24,344 shares | -0% | |
| 35Weak | HLSQsell BiomX Inc. | Assaf Oron Chief Business Officer | $4,072 10,914 shares | -100% | |
| 27Weak | HLSQbuy BiomX Inc. | OrbiMed Israel BioFund GP Limited Partnership owner | $85k 348,000 shares | +12% | |
| 20Weak | HLSQsell BiomX Inc. | Chidozie Ugwumba other | $184k 288,619 shares | -8% | |
| 18Weak | HLSQsell BiomX Inc. | Chidozie Ugwumba other | $107k 277,247 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.